Verona Pharma plc — Director's Dealing 2022

Apr 29, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2022-04-28

Reporting Person: Ullman Anders (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-28	Share Options (Right to Buy)	$0.5038	A	200000	Acquired	2032-04-27	Ordinary Shares (200000)	Direct

Footnotes

F1: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: The option vests and becomes exercisable as to 25% on each of July 28, 2022, October 28, 2022, January 28, 2023 and April 28, 2023.